Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: An experiment in vivo

Acta Radiologica

Volumn 54, Issue 2, 2013, Pages 199-204

  Xu, Ming ^a   Xie, Xiao Hua ^a   Xie, Xiao Yan ^a   Xu, Zuo Feng ^a   Liu, Guang Jian ^a   Zheng, Yan Ling ^a   Huang, Guang Liang ^a   Wang, Wei ^a   Zheng, Shu Guang ^a   Lü, Ming De ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Radiofrequency ablation; Sorafenib

Indexed keywords

ABLATION; MAMMALS; POLYMERASE CHAIN REACTION;

DIFFERENT TREATMENTS; ENDOTHELIAL GROWTH FACTOR; HEPATOCELLULAR CARCINOMA; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSIONS; RADIO-FREQUENCY ABLATION; RECURRENCE RATES; SORAFENIB;

TUMORS;

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE; SORAFENIB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CATHETER ABLATION; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; MALE; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHETER ABLATION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84876730154     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2012.120249     Document Type: Article

References (27)

1. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56: 908-43
2. Farinati F, Rinaldi M, Gianni S, et al. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000;89: 2266-73
3. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29: 62-7
4. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 2009;249: 20-5
5. Cho YK, Rhim H, Noh S. Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol 2011;26: 1354-60
6. Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242: 158-71
7. Svendsen MN, Werther K, Nielsen HJ, et al. VEGF and tumour angiogenesis. Impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol 2002;37: 373-9
8. van der Bilt JD, Kranenburg O, Nijkamp MW, et al. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005;42: 165-75
9. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3: 721-32
10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: 378-90
11. Wang Z, Zhou J, Fan J, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008;14: 5124-30
12. Hora C, Romanque P, Dufour JF. Effect of sorafenib on murine liver regeneration. Hepatology 2011;53: 577-86
13. Peng ZW, Lin XJ, Zhang YJ, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262: 1022-33
14. Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2006;22: 248-53
15. Koda M, Maeda Y, Matsunaga Y, et al. Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res 2003;27: 163-7
16. Portolani N, Tiberio GA, Ronconi M, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology 2003;50: 2179-84
17. Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 2003;8: 332-5
18. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92: 5510-4
19. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11: 72-82
20. Daskalow K, Rohwer N, Raskopf E, et al. Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma. J Mol Med (Berl) 2010;88: 817-27
21. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25: 581-611
22. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7
23. Yang ZF, Poon RT, To J, et al. The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res 2004;64: 5496-503
24. Yeo EJ, Chun YS, Park JW. New anticancer strategies targeting HIF-1. Biochem Pharmacol 2004;68: 1061-9
25. Hoffmann K, Glimm H, Radeleff B, et al. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008;8:349
26. Nilsson MB, Zage PE, Zeng L, et al. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 2010;29: 2938-49
27. Mertens JC, Martin IV, Schmitt J, et al. Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. Eur J Radiol 2012;81:1601-6